What differentiates Mesoblast’s technology from its competitors?
Mesoblast’s technology positively selects for a starting population of MPCs which is more than 1000-fold purer than that of its competitors. Mesoblast’s MPCs have been shown in clinical and preclinical studies to both create new blood vessels and stimulate cells at the site of damage to repair themselves, as well as providing functional cells to the region of tissue in need of repair. Because MPCs do not provoke an immune reaction, Mesoblast is developing allogeneic (unrelated recipient) stem cell products for treatment of various medical conditions, including cardiovascular and neurological diseases, diabetes and eye diseases as well as bone and cartilage degeneration. These are all rapidly growing, billion dollar markets.
